Estimaciones de analistas de Wall Street para Enliven Therapeutics, Inc. (ELVN): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-11 | $-0.43 | ||
| 2026-08-05 | $-0.49 | $-0.39 | -26.6% |
| 2026-05-07 | $-0.38 | $-0.44 | +13.6% |
| 2026-03-03 | $-0.48 | $-0.42 | -14.3% |
| 2025-11-12 | $-0.32 | $-0.43 | +25.6% |
| 2025-08-13 | $-0.49 | $-0.53 | +7.5% |
| 2025-05-14 | $-0.57 | $-0.51 | -11.8% |
| 2025-03-13 | $-0.46 | $-0.53 | +13.2% |
Cuenta de Resultados (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Ingresos | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Coste de Ventas | 0 | 0 | $33000 | 0 | 0 | 0 | 0 | 0 | $263000 |
| Beneficio Bruto | 0 | 0 | -$33000 | 0 | 0 | 0 | 0 | 0 | -$263000 |
| I+D | $7.9M | $8.2M | $19.0M | $8.2M | $20.5M | $31.0M | $64.6M | $80.8M | $85.9M |
| Generales y Administrativos | $987000 | $2.4M | $5.1M | $1.1M | $4.3M | $7.8M | $19.0M | $23.8M | $33.8M |
| Gastos Operativos | $8.9M | $10.7M | $24.1M | $9.3M | $24.8M | $38.8M | $83.5M | $104.6M | $119.4M |
| Beneficio Operativo | -$8.9M | -$10.7M | -$24.1M | -$9.3M | -$24.8M | -$38.8M | -$83.5M | -$104.6M | -$119.7M |
| EBITDA | $221000 | -$11.3M | -$23.4M | -$9.3M | -$24.6M | -$37.4M | -$71.3M | -$88.5M | -$103.4M |
| Gastos por Intereses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Antes de Impuestos | $221000 | -$11.3M | -$23.5M | -$19.0M | -$24.7M | -$37.7M | -$71.6M | -$88.8M | -$103.7M |
| Impuestos | $221000 | 0 | 0 | 0 | 0 | 0 | 0 | $232000 | 0 |
| Beneficio Neto | 0 | -$11.3M | -$23.5M | -$19.0M | -$24.7M | -$37.7M | -$71.6M | -$89.0M | -$103.7M |
| BPA | $0.00 | $-2.62 | $-5.43 | $-4.31 | $-3.17 | $-6.03 | $-2.01 | $-1.89 | $-1.83 |
| BPA Diluido | $0.00 | $-2.62 | $-5.43 | $-4.31 | $-3.17 | $-6.03 | $-2.01 | $-1.89 | $-1.83 |
| Acciones en Circulación (Diluidas) | $4.3M | $4.3M | $4.3M | $4.4M | $7.8M | $6.2M | $35.5M | $47.1M | $56.7M |
Precio
| Precio | $49.12 |
| Capitalización | $3.5B |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: ATAI · DNTH · IMTX · INBX · NKTR · ORIC · PGEN
Explorar sector: Healthcare · Biotechnology
Más secciones de ELVN: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones